195510-91-9

Basic information

• Product Name: (R)-3-(tert-butyldimethylsilanyloxy)-4-{3-[3-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)ureido]benzyloxycarbonylamino}butyric acid methyl ester
• Synonyms: (R)-3-(tert-butyldimethylsilanyloxy)-4-{3-[3-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)ureido]benzyloxycarbonylamino}butyric acid methyl ester
• CAS NO: 195510-91-9
• Molecular Weight: 687.868
• Mol File: 195510-91-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (R)-3-(tert-butyldimethylsilanyloxy)-4-{3-[3-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)ureido]benzyloxycarbonylamino}butyric acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-3-(tert-butyldimethylsilanyloxy)-4-{3-[3-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)ureido]benzyloxycarbonylamino}butyric acid methyl ester(195510-91-9)
• EPA Substance Registry System: (R)-3-(tert-butyldimethylsilanyloxy)-4-{3-[3-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)ureido]benzyloxycarbonylamino}butyric acid methyl ester(195510-91-9)

Safety Data

• Hazardous Substances Data: 195510-91-9(Hazardous Substances Data)

Upstream product

• 109462-20-6 1-methyl hydrogen 3-<(tert-butyl)dimethylsilyloxy>glutarate 
• 153825-72-0 1-(3-Hydroxymethyl-phenyl)-3-((R)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea 
• 195510-90-8 3-(tert-butyldimethylsilanyloxy)-4-isocyanatobutyric acid methyl ester 

Downstream Products

• 195510-93-1 [3-[3-(3-Piperidin-1-ylmethyl-phenoxy)-propylcarbamoyl]-2-(tetrahydro-pyran-2-yloxy)-propyl]-carbamic acid 3-[3-((R)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-ureido]-benzyl ester 
• 195510-92-0 (R)-3-hydroxy-4-{3-[3-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)ureido]benzyloxycarbonylamino}butyric acid methyl ester 

Relevant articles and documents

Synthesis and structure-activity relationships of dual histamine H2 and gastrin receptor antagonists with decreased hydrophobicity

In order to study structure-activity relationships of the previously reported dual histamine H2 and gastrin receptor antagonists and also to improve their low oral absorbability, we tried two chemical modifications. One tried to decrease the high hydrophobicity of the parent hybrid compounds to an appropriate level by incorporating a hydrophilic group into the molecule and the other by replacing the more hydrophobic groups with less hydrophobic ones. The former compounds (type I) involved hybrid compounds with a hydroxyl group at a position of a spacer, a piperidine moiety of H2A, or a phenyl ring at the C5 of the benzodiazepine skeleton as well as those with a free carboxyl group in the piperidine moiety of H2A. The latter (type II) involved hybrid compounds with the C5-phenyl group replaced with either a methyl group or hydrogen atom. Among them, only a type I compound, ({2-[3-(3-piperidin-1 -ylmethylphenoxy)propylcarbamoyl]ethylcarbamoyl}methyl)carbamic acid 3-{3-[5-(3-hydroxy- phenyl)-1-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]ureido}benzyl ester (18), showed potent dual histamine H2 and gastrin receptor antagonistic activity, whereas others resulted in a significant decrease of histamine H2 receptor antagonistic activity. The in vivo gastric acid antisecretory activity of 18 evaluated by Schild's rat method, however, did not suggest any notable improvement in oral absorbability.